Target intelligence / Profile preview

Novel transcript, antisense to NFIB (ENSG00000289969)

Target
ENSG00000289969
Molecular classification
Long non-coding RNA (lncRNA), Natural antisense transcript
01

Overview

ENSG00000289969 encodes a long non-coding RNA transcript that is transcribed antisense to the NFIB gene. Natural antisense transcripts like this are typically not translated into protein but can regulate the expression of the overlapping sense gene through diverse mechanisms, including transcriptional interference, RNA duplex formation, and epigenetic modification. While the NFIB gene encodes a transcription factor involved in cell differentiation and cancer, the functional significance of this specific antisense transcript has not been experimentally determined[4]. There are no known drug interactions or clinical applications related to this transcript.

02

Mechanism of action

None established; generally, antisense lncRNAs can modulate sense gene expression through transcriptional interference, RNAi mechanisms, or chromatin remodeling, but this is not demonstrated for this transcript[1].

03

Biological functions

Possible regulation of NFIB gene expression via antisense interference or chromatin modification, by analogy to other antisense lncRNAsOther functions not experimentally established for this specific transcript.
04

Disease associations

Other (as non-coding RNAs are frequently associated with gene regulation, but no direct disease association reported for this specific antisense transcript; the sense gene NFIB is involved in developmental disorders and cancers[3][5][6], but not necessarily this antisense RNA itself)
05

Safety considerations

None reported; as a non-coding RNA, its therapeutic or off-target liability has not been discussed

Beyond the preview

Go deeper on Novel transcript, antisense to NFIB (ENSG00000289969).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel transcript, antisense to NFIB (ENSG00000289969).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call